(Q47233232)

English

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

scientific article published on 22 February 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial (English)

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

0 references

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Arne Astrup

2

0 references

Xavier Pi-Sunyer

11

object named as

Xavier Pi-Sunyer

1 reference

Europe PubMed Central

12 January 2018

Frank L Greenway

4

object named as

Frank Greenway

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

Troshina Ekaterina

1 reference

ORCID Public Data File 2021

Ferruccio Santini

1 reference

ORCID Public Data File 2021

author name string

Carel W le Roux

1

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

Ken Fujioka

3

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

David C W Lau

5

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

Luc Van Gaal

6

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

Rafael Violante Ortiz

7

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

John P H Wilding

8

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

Trine V Skjøth

9

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

Linda Shapiro Manning

10

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

SCALE Obesity Prediabetes NN8022-1839 Study Group

12

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

language of work or name

0 references

publication date

22 February 2017

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

389

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

10077

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

1399-1409

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediabetes: a high-risk state for diabetes development.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a brief measure to assess quality of life in obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of the Treatment Related Impact Measure of Weight (TRIM-Weight).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Missing data in clinical trials for weight management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone for diabetes prevention in impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide exerts a potent antiinflammatory effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gallstones in obesity and weight loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930069-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)30069-7

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/28237263

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47233232&oldid=2147192673"